Abstract
Synchrobreathe® is a novel breath actuated pressurised metered dose inhaler (pMDI) with a dose counter. This study was designed to evaluate local lung deposition when salmeterol and fluticasone propionate (SFC) combination was delivered from the single actuation by Synchrobreathe device compared with the conventional pMDI device in patients with stable asthma.
In this prospective, randomized, open-label, cross-over, two-period, single-dose study, 10 stable adult patients with asthma received one puff of radiolabelled (99mTC) SFC (25/125mcg) via either the Synchrobreathe or conventional pMDI (both Cipla Ltd, India) on the first treatment day, and via the alternative device on the second treatment day. The two dosing days were separated by a washout period of 7 days. The percentage of the actuated drug deposited in the lungs at 5 min post dose was analysed using the gamma scintigraphy. Pre- and 2 h post- dose FEV1 and safety were also measured.
A significantly (p<0.05) higher drug deposition was observed when SFC was delivered via Synchrobreathe device (22.33%) as compared with the conventional pMDI (17.32%). The pre- and post-dose FEV1 values were not significantly different when SFC is given via synchrobreathe versus pMDI. The treatment was well tolerated with both the devices.
Salmeterol/fluticasone given with the Synchrobreathe device achieves better lung deposition compared to a conventional pMDI.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4222.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019
